phrykt

Celldex Therapeutics, Inc. (CLDX): who owns it and who trades it

As of Nov 16, 2026, CLDX insiders reported 1 open-market sale worth $121K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Freddy A. Jimenez (Vice president), with $121K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Celldex Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CLDX

252 funds and institutions reported CLDX shares worth $3.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Wellington Management Group LLP with 12.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Wellington Management Group LLP12.2%
BlackRock, Inc.8.9%
Kynam Capital Management, LP6.8%
T. Rowe Price Associates6.0%
State Street Corp5.0%
FMR LLC (Fidelity)4.7%
Vanguard Capital Management LLC4.4%
Deep Track Capital, LP3.7%
California State Teachers Retirement System3.7%
Logos Global Management LP2.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Wellington Management Group LLP9.54M12.16%$355M+11%
BlackRock, Inc.7.00M8.92%$261M+30%
Kynam Capital Management, LP5.32M6.78%$198M-9%
T. Rowe Price Associates4.69M5.97%$174M+125%
State Street Corp3.90M4.97%$145M+39%
FMR LLC (Fidelity)3.72M4.74%$139M-1%
Vanguard Capital Management LLC3.46M4.41%$129M+17%
Deep Track Capital, LP2.94M3.74%$109M+129%
California State Teachers Retirement System2.89M3.68%$77.7M+3532%
Logos Global Management LP2.10M2.68%$78.1M+367%
Geode Capital Management, LLC2.02M2.58%$75.3M+20%
Eversept Partners, LP1.79M2.28%$66.5M-0%
Goldman Sachs Group Inc1.62M2.06%$60.1M+63%
Assenagon Asset Management S.A.1.58M2.01%$58.7M+977%
Commodore Capital LP1.35M1.72%$50.2M-50%
Bellevue Group AG1.20M1.53%$44.7MNo change
Baker Bros. Advisors LP1.18M1.51%$44M+78%
Millennium Management LLC1.17M1.49%$43.6M-7%
Dimensional Fund Advisors LP1.07M1.37%$40M+1%
American Century Companies Inc1.04M1.33%$38.8M+22%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CLDX insiders reported $0 of open-market purchases and $121K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$121K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Dec 4, 2025
Filed Dec 8, 2025

Purchases and sales by month

$121K$121KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 4, 2025Freddy A. JimenezVice presidentSale4,166$29.10$121KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Freddy A. JimenezSVP & GENERAL COUNSEL–$121KDec 4, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CLDX short interest

High short interest. 12.7% of CLDX shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 39%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.94M CLDX shares were sold short, 12.7% of the shares outstanding, up 3.5% from the report before. At the average daily volume of 959,849 shares, buying them all back would take about 10.3 trading days (days to cover).

Shares short, % of all shares

12.7%May 15Oct 3014.8%

Days to cover

10.3May 15Oct 3014.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.94M12.65%+4%959,84910.3
Oct 15, 20269.60M12.22%-13%1.63M5.9
Sep 30, 202611.01M14.02%+23%2.89M3.8
Sep 15, 20268.95M11.40%+4%682,56413.1
Aug 31, 20268.64M11.00%+14%706,59612.2
Aug 14, 20267.57M9.64%-1%954,7757.9
Jul 31, 20267.63M9.71%-0%1.00M7.6
Jul 15, 20267.66M9.76%-1%838,1219.1
Jun 30, 20267.74M9.86%+6%1.80M4.3
Jun 15, 20267.30M9.29%+2%805,7839.1
May 29, 20267.14M9.10%+0%665,61310.7
May 15, 20267.13M9.08%-6%708,67610.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Celldex Therapeutics company events

Celldex Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 22, 2026AnnouncementCelldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jul 15, 2026LeadershipSam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc., notified the Company of his plans to retire effective on or about March 31, 2027. Filing
  5. Jun 26, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Celldex Therapeutics, Inc., the Company’s stockholders approved an amendment to the Company’s 2021 Omnibus Equity Incentive Plan (i) increasing the number of shares available for issuance under the 2021 Plan by 3,400,000 shares and (ii) clarifying the… Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Apr 2, 2026AgreementCelldex Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein, relating to the offering, issuance and sale of 10,345,000 shares of the Company’s common stock, par value $0.001, at… Filing
  8. Feb 25, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Celldex Therapeutics financials

Famous investors that hold CLDX

5 of the 50 well-known investors we track reported holding CLDX in their latest 13F filing. The largest position is Ken Fisher's, worth $40.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 20261.25M$40.4M0.0%+26%
Israel Englander · Millennium ManagementQ3 2026337,487$10.9M0.0%-71%
Jim Simons · Renaissance TechnologiesQ3 202667,788$2.2M0.0%New
Steve Cohen · Point72 Asset ManagementQ3 202665,405$2.1M0.0%-44%
Paul Tudor Jones · Tudor Investment CorpQ3 202615,096$489K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named CLDX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Wellington Management Group LLP13G/A13.9%
Nov 16, 2026Wellington Management Group LLP13G/A13.9%
Oct 7, 2026FMR LLC13G/A10.7%
Oct 7, 2026FMR LLC13G/A10.7%

Questions about Celldex Therapeutics, Inc. (CLDX) stock

Who owns the most CLDX stock?

The largest reported owner of Celldex Therapeutics, Inc. (CLDX) is Wellington Management Group LLP, with 12.2% of the company. In total, 252 funds and institutions reported holding CLDX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are CLDX insiders buying or selling?

In the last 12 months, CLDX insiders reported no open-market purchases and 1 sale worth $121K. The latest trade was on Dec 4, 2025. See every trade.

What is the short interest in CLDX?

As of Oct 30, 2026, 9.94M CLDX shares were sold short, 12.7% of the shares outstanding, up 3.5% from the report before. At the average daily volume of 959,849 shares, buying them all back would take about 10.3 trading days (days to cover). See the history.

Which famous investors hold CLDX?

5 of the 50 well-known investors we track reported CLDX in their latest 13F filing, including Ken Fisher, Israel Englander, Jim Simons. The largest position is worth $40.4M. See all holders.

Executive pay

Celldex Therapeutics's chief executive was paid a total of $5.4M for the year ended Dec 31, 2025, down 42% from $9.2M the year before. In the last 12 months, Celldex Therapeutics's executives and directors bought no stock on the open market and sold $1.3M.

Chief executive, total pay$5.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$4.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.9MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.